How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
When it Comes to API Manufacturing, Face Masks and Clean Environments Have Always Been Part of Life
How to Select a CMO
Paving the Way for a Smooth FDA Inspection
Cryogenics: How Cryogenic Capabilities Aid API Development
Generic Drug Makers Continue to Face Hurdles in Race to Make Drugs More Affordable